Global Retinal Biologics Market to Reach USD 41.92 Billion by 2028 at a 11.1% of CAGR

The Retinal Biologics Market generated USD 19.96 billion in revenue in 2021 and is projected to grow to USD 41.92 billion by 2028, expanding at a CAGR of 11.1% from 2022 to 2028. In 2021, retinal biologics accounted for 6.9% of the global biologic therapeutics market.

Request a Sample of this Report Now: https://www.futuremarketinsights.com/report-sample#5245502d47422d38363633

Key Market Drivers:

1. Rising Prevalence of Retinal Disorders:

   • Increasing cases of age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are driving demand for retinal biologics.
   • AMD is the leading cause of vision loss in people over 50, while diabetic retinopathy affects approximately one-third of diabetics globally.

2. Growing Geriatric Population:

   • An aging global population is at a higher risk of developing retinal disorders, leading to increased demand for advanced biologic therapies.
   • WHO projects that by 2050, the global population aged 60 and above will double, contributing to the rise in retinal diseases.

3. Technological Advancements in Retinal Biologics:

   • Development of targeted biologics and gene therapies is transforming retinal disease management.
   • Anti-VEGF (Vascular Endothelial Growth Factor) therapies, such as Ranibizumab and Aflibercept, are widely used for treating wet AMD and diabetic macular edema.
   • Gene therapies, including Luxturna (voretigene neparvovec), are paving the way for precision medicine in retinal care.

4. Increasing Adoption of Minimally Invasive Treatment Options:

   • Intravitreal injections and implants offer targeted drug delivery with minimal side effects, enhancing patient compliance.
   • Growing preference for minimally invasive procedures is driving the adoption of long-acting injectable biologics.

5. Favorable Reimbursement Policies and Government Support:

   • Government initiatives and favorable reimbursement policies are encouraging accessibility and affordability of retinal biologics.
   • Medicare and private insurers in the US cover advanced retinal treatments, boosting market penetration.

Market Trends:

• Shift Toward Gene Therapies and Regenerative Medicine:
  • Gene therapies are gaining traction for inherited retinal disorders, offering curative potential.
  • CRISPR-Cas9 technology is being explored for genetic mutation correction in retinal diseases.
• Development of Long-Acting Biologics and Sustained-Release Implants:
  • Sustained-release implants and long-acting injectables reduce the treatment burden by minimizing injection frequency.
  • Port Delivery Systems (PDS) and nanoparticle-based drug delivery are emerging as innovative solutions.
• Rising Focus on Personalized Medicine:
  • Personalized treatment approaches based on genetic profiling and biomarkers are enhancing treatment efficacy and safety.
• Strategic Collaborations and Partnerships:
  • Pharmaceutical companies are engaging in strategic collaborations with biotech firms and academic institutions for R&D and product innovation.

Therapeutic Applications:

• Age-Related Macular Degeneration (AMD):
  • Wet AMD: Treated with Anti-VEGF therapies like Ranibizumab (Lucentis), Aflibercept (Eylea), and Brolucizumab (Beovu).
  • Dry AMD: Increasing focus on gene therapies and complement inhibitors for disease modification.
• Diabetic Retinopathy and Diabetic Macular Edema:
  • Anti-VEGF agents and Corticosteroid implants for vision restoration and disease control.
  • Faricimab (Vabysmo), a bispecific antibody, offers dual inhibition of VEGF and Ang-2, enhancing therapeutic efficacy.
• Retinal Vein Occlusion (RVO):
  • Anti-VEGF treatments and intravitreal corticosteroids for macular edema management.
• Inherited Retinal Diseases:
  • Gene therapies, including Luxturna (voretigene neparvovec), for RPE65 mutation-associated retinal dystrophy.
  • Ongoing research on optogenetics and stem cell therapies for retinal regeneration.

Access the Full Report: https://www.futuremarketinsights.com/reports/retinal-biologics-market

Challenges:

• High Cost of Biologic Therapies:
  • Advanced biologics are expensive, limiting accessibility in cost-sensitive regions.
• Regulatory and Reimbursement Challenges:
  • Stringent regulatory approvals and complex reimbursement processes can delay market entry and product adoption.
• Side Effects and Safety Concerns:
  • Intravitreal injections may lead to ocular inflammation, endophthalmitis, and retinal detachment.
• Competition from Biosimilars and Generic Alternatives:
  • Biosimilars are gaining traction due to cost-effectiveness, posing a challenge to branded biologics.

Competitive Landscape:

Leading companies are focusing on product innovation, strategic acquisitions, and R&D investments. Key players include:

• Regeneron Pharmaceuticals Inc. – Offers Eylea (Aflibercept), a leading Anti-VEGF therapy for retinal disorders.
• Novartis AG – Markets Lucentis (Ranibizumab) and Beovu (Brolucizumab) for wet AMD and diabetic macular edema.
• Roche Holding AG – Developed Faricimab (Vabysmo) for dual inhibition of VEGF and Ang-2.
• Biogen Inc. – Focuses on gene therapies for inherited retinal diseases.
• Spark Therapeutics (Roche) – Launched Luxturna (voretigene neparvovec) for RPE65 mutation-related retinal dystrophy.
• Allergan (AbbVie Inc.) – Developing Sustained-release implants for long-term retinal disease management.

Key Takeaways:

• The Retinal Biologics Market is projected to grow at a CAGR of 11.1%, reaching USD 41.92 billion by 2028.
• Rising prevalence of retinal disorders, technological advancements, and targeted therapies are driving market growth.
• North America dominates, while Asia-Pacific is the fastest-growing region.
• High costs, regulatory challenges, and competition from biosimilars pose challenges.
• Product innovation, strategic partnerships, and R&D investments are key growth strategies.

Key Companies Profiled

Spark Therapeutics, Inc.; F. Hoffmann-La Roche Ltd.; Regeneron Pharmaceuticals, Inc.; AbbVie Inc.; Amgen Inc.; Novartis Pharma AG; MeiraGTx Limited; Oxurion NV; Santen Pharmaceutical Co., Ltd.; Bayer AG; Bausch Health Companies Inc.; Merck & Co., Inc.

Key Segments of Retinal Biologics Industry Survey

Retinal Biologics Market by Drug Class:

• VEGF-A Antagonists
• TNF-α Inhibitors

Retinal Biologics Market by Indication:

• Macular Degeneration
• Diabetic Macular Edema
• Diabetic Retinopathy
• Uveitis
• Others

Retinal Biologics Market by Distribution Channel:

• Institutional Sales
• Retail Pharmacies
• Mail Order Pharmacies
• Retail Sales

Retinal Biologics Market by Region:

• North America Retinal Biologics Market
• Latin America Retinal Biologics Market
• Europe Retinal Biologics Market
• East Asia Retinal Biologics Market
• South Asia & Pacific Retinal Biologics Market
• Middle East & Africa (MEA) Retinal Biologics Market

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centres in the United Kingdom, the United States, and India. FMI’s latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.

Contact Us

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube